Call Us: 1.800.873.5297

By

FDA Places Harsh Restrictions on Avandia

WASHINGTON, DC – The US Food and Drug Administration (FDA) announced new, severe restrictions on GlaxoSmithKline’s heavily scrutinized diabetes medication Avandia on Thursday, September 23. The European Medicines Agency announced the same day that Avandia was to be completely removed from the market in Europe.

FDA’s decision has raised the profile of Avandia’s health risks, which have been in the news for months. So far, Avandia has been linked to an increased risk of:

  • •Heart disease
  • •Heart failure and heart attacks
  • •Bladder cancer
  • •Pulmonary embolism
  • •Stroke
  • •Bone fractures

If you or someone you know has developed any of the above conditions after taking Avandia, you may have grounds for an Avandia defective drug lawsuit. The pharmaceutical injury law firm of Schlichter, Bogard & Denton has a strong record in pharmaceutical injury litigation and is ready to help you build your case and seek fair financial compensation.

Suppressing Risks and Scratching Backs

In fact, there is evidence that GSK knew about the risk of heart attacks even before Avandia was approved by the FDA in 2000, but hid the evidence from regulators. In addition, some members of FDA panels that issued earlier regulatory decisions on Avandia have in the past received payments from GSK for speaking engagements. These shady practices and conflicts of interest in the FDA’s approval process and regulatory process are likely to be factors in Avandia defective drug lawsuits nationwide.

Even before the FDA’s September 23rd decision to allow only patients who do not respond to any other diabetes medication access to Avandia, plaintiffs across the United States had already been bringing defective drug lawsuits for Avandia-related heart attacks. Reuters reported in July that GSK had agreed to $460 million in Avandia settlements to about 10,000 plaintiffs.

Now that the FDA has severely restricted Avandia, judges and juries will likely find Avandia pharmaceutical injury claims against GSK more credible.

If you or a loved one has developed heart problems or had a heart attack or stroke after taking Avandia, please contact the defective drug injury attorneys of Schlichter, Bogard & Denton today to discuss your legal options.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.